Engineered for Pharmaceutical-Grade Performance
We bridge the gap between complex molecular discovery and reliable commercial implementation. Our proprietary PDRN polynucleotide oral delivery platform is engineered to solve bioavailability constraints, providing pharmaceutical-grade precision for next-generation biotechnology solutions.
Scientific Mechanism
Our proprietary oral delivery system uses a pharmaceutical-grade delayed-release enteric capsule that protects the PDRN payload through the acidic gastric environment and releases it in the small intestine, where absorption occurs. No injectable. No clinic. No compromise on bioavailability.
By precisely engineering the molecular interface of each complex, we ensure that pharmaceutical-grade compounds remain stable through the gastrointestinal tract, significantly enhancing systemic bioavailability and clinical reliability.
The Polymor Complex utilizes a patent-pending cofactor stack, protected by an active US provisional filing with 20 independent claims covering the formulation, delivery system, and method of use. The complex is designed to maximise the bioavailable fraction of each active, ensuring delivery at a clinically meaningful level.
Improved Bioavailability
Our engineered delivery systems utilize pharmaceutical-grade mechanisms to ensure maximum absorption and metabolic efficiency.
Patentable Complexes
We deliver unique, defensible IP protected by active patent filings, giving our partners a foundation for market exclusivity and long-term commercial value.
Mechanism-Backed
Every complex in our pipeline is built upon years of peer-reviewed clinical data and strictly validated biological pathways.
Scalable Delivery
Engineered for pharmaceutical-grade performance across diverse formulations and high-volume commercial production.